Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.

McIntyre, Roger S

doi:10.1080/14740338.2023.2248883

Record: found
Abstract: not found
Article: not found

Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.

Author(s): Roger S McIntyre ¹ ^, ² ^, ³

Publication date (Electronic): 2023

Journal: Expert opinion on drug safety

Publisher: Informa UK Limited

Keywords: 5HT2B receptor agonism, FDA guidance, Lysergic acid diethylamide (LSD), Psilocybin, ecstasy, valvular heart disease

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 20

Record: found
Abstract: not found
Article: not found

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Guy M. Goodwin, Scott Aaronson, Oscar Álvarez … (2022)

0 comments Cited 187 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies

Kristoffer Andersen, Robin Carhart-Harris, David J Nutt … (2021)

To conduct a systematic review of modern-era (post-millennium) clinical studies assessing the therapeutic effects of serotonergic psychedelics drugs for mental health conditions. Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experiences were also reviewed and presented.